VANFLYTA 17.7 mg
As listed in the register: VANFLYTA 17.7 mg, Filmtabletten
17.7 mg ·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Quizartinibum
- Made by
- Daiichi Sankyo (Schweiz) AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Erwachsene Patienten mit akuter myeloischer Leukämie (AML), die FLT3-ITD-positiv ist
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Daiichi Sankyo (Schweiz) AG |
|---|---|
| Active substance | Quizartinibum |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 17.7 mg |
| Classification | L01EX11 · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | VANFLYTA 17.7 mg, Filmtabletten |
| Packs | 14 Tablette(n) · 28 Tablette(n) |
| Zulassungsnummer | 69710 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.